Mandate

Vinge advises Smart Eye in a directed new share issue of MSEK 200

May 22, 2019

Vinge has advised Smart Eye AB (Nasdaq First North) on a directed new share issue that provides Smart Eye with approximately MSEK 200.

The subscription price, i.e. SEK 101.50, has been determined by an accelerated book‑building procedure corresponding to a discount of 1.6 per cent compared to the closing price on Nasdaq First North on 21 May 2019. Första AP‑fonden becomes a new major shareholder in the company after having been allotted more than half of the shares in the new issue and thereby becomes the third largest owner with 6.6 per cent of the shares and votes. In total, five major Nordic institutions were allotted approximately 75 per cent of the shares in the new share issue. The purpose of the new share issue is to finance the continued development of the business and an expanded offer towards the Chinese market. Carnegie Investment Bank has acted as sole bookrunner.

Vinge’s team has primarily consisted of responsible partner Anders Strid together with Wibeke Sorling and Edin Agic (Capital Markets), Gu Qun (China Practice), Alexander Lindeberg (IP), Victor Ericsson (Tax) as well as company assistant Camilla Andersson.

 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026